← ANALYST RATINGS · TIPRANKS
Tango Therapeutics (TNGX): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy1 Hold0 Sell
Ratings of 6 analysts in the last 3 months · top analysts only12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $41.20, the highest $68.00, the lowest $24.00. The average is +86.9% from the last price of $22.04.
Analyst ratings 17
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Sharon Zackfia★★★★★★★★★★#4054 · hits 44% · avg +3.0% | William Blair | $42.00 | Buy | +90.6% | Initiated | 15.10.26on TipRanks Oct 16 05:55 | +2.0%next day −1.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $22.50 → $22.00−2.2% | Hold | −0.2% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $21.50 → $22.00+2.3% | Hold | −0.2% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $21.50 → $21.00−2.3% | Hold | −4.7% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $22.00 → $22.50+2.3% | Hold | +2.1% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | — | Buy | — | Reiterated | 13.10.26on TipRanks 08:55 | −8.1%next day +0.9% | ↗ |
| John Newman★★★★★★★★★★#3035 · hits 44% · avg +4.1% | Canaccord Genuity | $46.00 | Buy | +108.7% | Reiterated | 12.10.26on TipRanks 06:50 | +1.6%next day −8.1% | ↗ |
| John Newman★★★★★★★★★★#3035 · hits 44% · avg +4.1% | Canaccord Genuity | $42.00 → $46.00+9.5% | Buy | +108.7% | Reiterated | 08.10.26on TipRanks 07:10 | +3.8%next day +4.9% · 5 days +0.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $26.00 → $22.50−13.5% | Hold | +2.1% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $25.00 → $21.50−14.0% | Hold | −2.5% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $25.00 → $22.00−12.0% | Hold | −0.2% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $25.00 → $21.50−14.0% | Hold | −2.5% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $26.00 → $22.00−15.4% | Hold | −0.2% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $26.00 → $22.00−15.4% | Hold | −0.2% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| Kelsey Goodwin★★★★★★★★★★#203 · hits 68% · avg +62.4% | Piper Sandler | $24.00 | Hold | +8.9% | Reiterated | 01.10.26on TipRanks 07:08 | −2.2%next day −5.7% · 5 days −9.0% | ↗ |
| John Newman★★★★★★★★★★#3035 · hits 44% · avg +4.1% | Canaccord Genuity | $46.00 | Buy | +108.7% | Reiterated | 24.09.26on TipRanks 07:10 | +0.8%next day +0.6% · 5 days −0.3% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $35.00 | Buy | +58.8% | Reiterated | 24.09.26on TipRanks 07:10 | +0.8%next day +0.6% · 5 days −0.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $22.50 → $26.00+15.6% | Hold | +18.0% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $21.00 → $25.00+19.0% | Hold | +13.4% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $21.50 → $25.00+16.3% | Hold | +13.4% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $21.00 → $25.00+19.0% | Hold | +13.4% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $21.50 → $26.00+20.9% | Hold | +18.0% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $22.00 → $26.00+18.2% | Hold | +18.0% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $66.00 → $68.00+3.0% | Buy | +208.5% | Reiterated | 18.08.26on TipRanks 06:30 | +1.3%next day −1.2% · 5 days −2.4% | ↗ |
| Laura Prendergast★★★★★★★★★★#345 · hits 76% · avg +52.4% | Stifel Nicolaus | $40.00 | Buy | +81.5% | Reiterated | 17.08.26on TipRanks 07:20 | −0.7%next day +1.3% · 5 days −1.9% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $33.00 → $39.00+18.2% | Buy | +77.0% | Reiterated | 12.08.26on TipRanks 08:30 | −3.1%next day −0.4% · 5 days −1.0% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $46.00 | Buy | +108.7% | Initiated | 15.07.26on TipRanks 05:15 | +1.6%next day −8.1% · 5 days −6.1% | ↗ |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $60.00 | Buy | +172.2% | Upgrade | 26.06.26on TipRanks Jun 25 16:15 | +5.1%next day +1.8% · 5 days −7.9% | ↗ |
| Yuan Zhi★★★★★★★★★★#1180 · hits 41% · avg +20.7% | B. Riley Securities | $21.00 → $35.00+66.7% | Buy | +58.8% | Assigned | 09.06.26on TipRanks Jun 8 11:25 | +52.7%next day +2.3% · 5 days +4.3% | ↗ |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | $35.00 | Buy | +58.8% | Upgrade | 08.06.26on TipRanks 11:50 | +52.7%next day +2.3% · 5 days +4.3% | ↗ |
| Kelsey Goodwin★★★★★★★★★★#203 · hits 68% · avg +62.4% | Piper Sandler | $16.00 → $24.00+50.0% | Hold | +8.9% | Downgrade | 15.05.26on TipRanks May 14 17:20 | −16.1%next day +0.4% · 5 days −2.4% | ↗ |
| Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% | Leerink Partners | $28.00 → $55.00+96.4% | Buy | +149.5% | Assigned | 15.05.26on TipRanks May 14 14:55 | −3.3%next day −16.1% · 5 days −12.3% | ↗ |
| Peter Lawson★★★★★★★★★★#602 · hits 47% · avg +15.5% | Barclays | $13.00 | Buy | −41.0% | Reiterated | 04.11.25on TipRanks Nov 5 03:50 | +1.2%next day −6.6% · 5 days +3.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Tango Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $42.57 at a price of $24.95 (+70.6%); now: $42.00 at $22.04 (+90.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 6 | 4 | 3 |
| Buy | 9 | 7 | 8 | 7 | 3 | 3 |
| Hold | 2 | 2 | 2 | 0 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.35 (from $-0.42 to $-0.30). Last quarter: $-0.37.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Tango Therapeutics
- CEO: Malte Peters
- Employees: 137
- 201 Brookline Avenue, Boston, MA, 02215, US
- www.tangotx.com
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 32 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗